Am J Transplant, Volume 16, Suppl 3 Archives - Page 44 of 180 - ATC Abstracts

2016 American Transplant Congress
Pre-Transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-Transplant Outcomes: A National Study.
M. Nazzal,¹ J. Chen,¹ K. Lentine,¹ M. Schnitzler,¹ J. Tuttle-Newhall,² C. Varma,¹ A. Taha,¹ A. Said,¹ H. Xiao,¹ H. Randall.¹
¹Saint Louis Univ, Saint Louis; ²East Carolina Univ, Greenville.
Currently most transplant centers use loco-regional therapy to bridge liver transplant (LT) candidates with hepatocellular carcinoma (HCC). However, limited data are available to support the…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
The Impact of Share 35 on Liver Allocation and Utilization: One DSA's Experience.
J. Orlowski, C. Muse, J. Whaley, R. Squires.
LifeShare of Oklahoma, Oklahoma City, OK.
Background: In June 2013, U.S. liver allocation changed from a local-regional-national model to “Share 35”, broadening sharing to a regional level based upon recipient MELD…
2016 American Transplant Congress
Mechanisms of Alloantigen-Specific Regulation After Donor Specific Transfusion and Costimulatory Blockade in YFP-Foxp3/TdTomRed-Ebi3 Marker Mice.
Y. Tomita,¹ W. Bracamonte-Baran,¹ D. Vignali,² W. Burlingham.¹
¹Department of Surgery, Division of Transplantation, University of Wisconsin-Madison, Madison, WI; ²Department of Immunology, University of Pittsburgh, Pittsburgh.
Background: In mice, donor specific transfusion (DST) plus anti-CD40L costimulatory blockade (MR-1) treatment is a standard and successful protocol to induced donor-specific transplant tolerance. Hypothesis:…
2016 American Transplant Congress
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
CMV-seronegative kidney transplant recipients (KTRs) from CMV-seropositive donors are at highly increased risk of primary CMV-infection with associated inferior outcomes after kidney transplantation. Presence of…
2016 American Transplant Congress
BATF Deficiency in Tolerant Lung Allograft Recipients Are Resistant to Anti-MHC and Anti-Self-Antigen Mediated Pathogenesis of Obliterative Airway Disease.
Z. Xu,^1,2 X. Lin,¹ M. Gunasekaran,^1,2 M. Sharma,^1,2 A. Gelman,¹ T. Mohanakumar.^1,2
¹Washington Univ Sch Med, St. Louis, MO; ²Norton Thoracic Institute - St. Joseph's Hospital, Phoenix, AZ.
Antibodies (Abs) to donor MHC and lung self-antigens (SAgs) administered following induction of lung allograft tolerance by co-stimulation blockade can result in breaking of tolerance…
2016 American Transplant Congress
Simultaneous Pancreas and Kidney Transplantation for Type 2 Diabetes.
K. Wong, W. Bry, H. Mahanty, P. Patel.
Transplantation, California Pacific Medical Center, San Francisco, CA.
Introduction: Type 2 diabetes (T2DM) is characterized initially by insulin resistance and later by beta cell failure. Historically, T2DM has been a relative contraindication for…
2016 American Transplant Congress
Prolongation of Graft Survival by Anti-TIM1 Is Specifically Mediated by IL-10+ Bregs and Is Not Dependent on IL-35 or Plasma Cell Differentiation.
Y. Zhou,^1,2 Q. Ding,¹ A. Cherukuri,¹ D. Rothstein.¹
¹Thomas E. Starzl Transplantation Institute, Departments of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²School of Medicine, Tsinghua University, Beijing, China.
In B cell-deficient mice, prolonged islet allograft survival (GS) mediated by anti-TIM1 depends on transfer of IL-10 competent B cells. However, such regulatory B cells…
2016 American Transplant Congress
Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance.
T. Simon, J. Bromberg.
University of Maryland, Baltimore, MD.
Background:Our recent work demonstrated that laminins α4β1γ1 and α5β1γ1, components of the lymph node (LN) stroma, are differentially regulated. Tolerance is associated with relatively higher…
2016 American Transplant Congress
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.
Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
University of Southern California, Los Angeles; University of Utah, Salt Lake City; Barnabas Health, West Orange; Novartis Pharmaceuticals Corporation, East Hanover.
The US92 study determined whether, in de novo renal transplant patients (pts), concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept®…